Attainment of LDL Cholesterol Treatment Goals in Children and Adolescents With Familial Hypercholesterolemia. The SAFEHEART Follow-up Registry
Por:
Saltijeral A., Pérez de Isla L., Alonso R., Muñiz O., Díaz-Díaz J.L., Fuentes F., Mata N., de Andrés R., Díaz-Soto G., Pastor J., Pinilla J.M., Zambón D., Pinto X., Badimón L., Mata P.
Publicada:
1 ene 2017
Resumen:
Introduction and objectives Little is known about the characteristics of persons with familial hypercholesterolemia (FH) younger than 18 years, the lipid-lowering therapy used in these patients, and the lipid goals reached in real life. Our aim was to evaluate the achievement of low-density lipoprotein cholesterol (LDL-C) treatment goals in FH patients younger than 18 years enrolled in a large national registry. Methods We analyzed patients younger than 18 years enrolled in a large ongoing registry of molecularly-defined patients with FH in Spain. The attainment of guideline-recommended plasma LDL-C goals at entry and follow-up was analyzed in relation to the use of lipid-lowering therapy. Results We enrolled 392 individuals younger than 18 years. Of these, 217 were molecularly-diagnosed FH patients and had a complete follow-up. The median follow-up time was 4.69 years (interquartile range, 2.48-6.38 years), 68.2% of FH patients were on statins, and 41.5% patients had LDL-C < 130 mg/dL. Statin use was the only predictor of LDL-C goal attainment. Conclusions This study shows that a high proportion of FH patients younger than 18 years have high LDL-C levels and fail to achieve recommended LDL-C targets. Statin use was the only independent predictor of LDL-C goal achievement. No safety concerns were detected during follow-up. These results indicate that many FH patients are not adequately controlled and that there is still room for treatment improvement. Full English text available from: www.revespcardiol.org/en © 2016 Sociedad Española de Cardiología
Filiaciones:
Saltijeral A.:
Sección de Cardiología, Hospital Universitario del Tajo, Universidad Alfonso X el Sabio, Aranjuez, Madrid, Spain
Pérez de Isla L.:
Servicio de Cardiología, Hospital Clínico San Carlos, Universidad Complutense de Madrid, IDISSC, Madrid, Spain
Alonso R.:
Servicio de Medicina Interna, Clínica las Condes, Santiago de Chile, Chile
Muñiz O.:
Servicio de Medicina Interna, Hospital Virgen del Rocío, Sevilla, Spain
Díaz-Díaz J.L.:
Servicio de Medicina Interna, Hospital Abente y Lago, A Coruña, Spain
Fuentes F.:
Unidad de Lípidos y Aterosclerosis, IMIBIC, Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain
Mata N.:
Departamento de Epidemiología, Consejería de Sanidad, Comunidad de Madrid, Madrid, Spain
de Andrés R.:
Servicio de Medicina Interna, Fundación Jiménez Díaz, Madrid, Spain
Díaz-Soto G.:
Departamento de Endocrinología, Hospital Clínico, Valladolid, Spain
Pastor J.:
Servicio de Pediatría, Hospital General Universitario de Elche, Alicante, Spain
Pinilla J.M.:
Centro de Salud San Miguel de Salinas, San Miguel de Salinas, Alicante, Spain
Zambón D.:
Clínica de Lípidos, Servicio de Endocrinología, Hospital Clínic, Barcelona, Spain
Pinto X.:
Servicio de Medicina Interna, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
Badimón L.:
Centro de Investigación Cardiovascular, Instituto Catalán de Ciencias Cardiovasculares, IIB-Sant Pau, Barcelona, Spain
Mata P.:
Fundación Hipercolesterolemia Familiar, Madrid, Spain
|